Go Pro
→ Buffett's Final Warning: 'The Dollar Is Going to Hell' (From Decentralized Masters) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$384.43
-1.7%		$400.14
$269.77
▼
$447.03
$207.89B0.432.70 million shs400,804 shs
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$30.25
-2.4%		$25.03
$16.01
▼
$36.29
$57.95B0.61385,834 shs65,229 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$143.86
-1.2%		$137.96
$108.46
▼
$157.29
$178.36B0.336.93 million shs566,980 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$518.13
-0.6%		$511.53
$374.17
▼
$560.25
$131.49B0.321.41 million shs95,121 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-0.48%-11.65%-6.22%+10.51%+39.75%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
-1.74%-0.96%+30.42%+61.96%-55.19%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-0.68%-2.65%+9.46%+15.71%+25.82%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-1.47%-6.40%-0.53%+17.10%+31.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$384.43
-1.7%		$400.14
$269.77
▼
$447.03
$207.89B0.432.70 million shs400,804 shs
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$30.25
-2.4%		$25.03
$16.01
▼
$36.29
$57.95B0.61385,834 shs65,229 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$143.86
-1.2%		$137.96
$108.46
▼
$157.29
$178.36B0.336.93 million shs566,980 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$518.13
-0.6%		$511.53
$374.17
▼
$560.25
$131.49B0.321.41 million shs95,121 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-0.48%-11.65%-6.22%+10.51%+39.75%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
-1.74%-0.96%+30.42%+61.96%-55.19%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-0.68%-2.65%+9.46%+15.71%+25.82%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-1.47%-6.40%-0.53%+17.10%+31.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.33
Hold$381.68-0.72% Downside
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
2.00
HoldN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.86
Moderate Buy$158.7810.37% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.96
Moderate Buy$569.529.92% Upside

Current Analyst Ratings Breakdown

Latest CSLLY, AMGN, GILD, and VRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Amgen Inc. stock logo
AMGN
Amgen
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$445.00 ➝ $425.00
9/10/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$155.00 ➝ $175.00
9/8/2026
Amgen Inc. stock logo
AMGN
Amgen
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$450.00
9/8/2026
Amgen Inc. stock logo
AMGN
Amgen
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$400.00
9/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$400.00 ➝ $435.00
9/1/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$665.00
9/1/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$653.00
8/31/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/25/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
8/20/2026
Amgen Inc. stock logo
AMGN
Amgen
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$427.00 ➝ $457.00
8/19/2026
Amgen Inc. stock logo
AMGN
Amgen
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$362.00
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$38.10B5.46$33.06 per share11.63$16.08 per share23.91
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$15.80B3.67$2.10 per share14.43$11.05 per share2.74
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$30.46B5.86$10.27 per share14.01$18.23 per share7.89
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$12.00B10.96$17.22 per share30.09$73.57 per share7.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$16.0923.9015.762.8322.95%124.14%13.18%11/3/2026 (Estimated)
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
-$2.58BN/AN/A17.392.28N/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B-$2.67N/A14.58N/A-10.64%-2.11%-0.75%10/29/2026 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.95B$17.1830.1628.132.2935.00%23.09%16.72%11/2/2026 (Estimated)

Latest CSLLY, AMGN, GILD, and VRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.62$6.29+$0.67$4.37$9.43 billion$10.05 billion
8/3/2026Q2 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$7.25-$6.75+$0.50-$8.45$7.40 billion$7.80 billion
8/3/2026Q2 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.74$4.73-$0.01$4.31$3.23 billion$3.33 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.62%+8.27%62.65%14 Years
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$0.591.95%N/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.282.28%+3.04%N/A 10 Years
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest CSLLY, AMGN, GILD, and VRTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.822.43%9/15/20269/15/20269/29/2026
7/30/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.29%8/21/20268/21/20269/11/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
4.44
1.37
1.13
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.51
2.57
1.15
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.03
1.27
1.09
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/A
3.19
2.74

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.03%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.85%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
N/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.30%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500540.63 million536.04 millionOptionable
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
29,9041.92 billionN/ANot Optionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,400253.80 million253.30 millionOptionable

Recent News About These Companies

Tidal Investments LLC Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tidal-investments-llc-boosts-stock-holdings-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-10/
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by National Pension Service
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-acquired-by-national-pension-service-2026-09-10/
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
September 10 at 5:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4944868-vertex-pharmaceuticals-incorporated-vrtx-presents-at-wells-fargo-21st-annual-healthcare
Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution
September 9 at 6:10 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4944230-vertex-pharmaceuticals-solid-growth-but-valuation-still-requires-flawless-execution?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by HighTower Advisors LLC
September 9 at 4:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-sold-by-hightower-advisors-llc-2026-09-09/
Carmignac Gestion Has $81 Million Position in Vertex Pharmaceuticals Incorporated $VRTX
September 8 at 7:11 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-carmignac-gestion-has-81-million-position-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-08/
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights
September 8 at 6:50 PM  |  zacks.comhttps://www.zacks.com/stock/news/2986677/vertex-pharmaceuticals-vrtx-suffers-a-larger-drop-than-the-general-market-key-insights?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v1-2986677
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
September 8 at 6:31 PM  |  fool.comhttps://www.fool.com/investing/2026/09/08/goldman-sachs-just-added-vertex-pharmaceuticals-to/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=a98a37ab-4495-40c2-ac9a-0f4d7a88160b
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights
September 8 at 6:29 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-vrtx-suffers-larger-215004539.html
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
September 8 at 6:29 PM  |  fool.comhttps://www.fool.com/investing/2026/09/08/goldman-sachs-just-added-vertex-pharmaceuticals-to/
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
September 8 at 1:28 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/investors-heavily-search-vertex-pharmaceuticals-130003081.html
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
September 8 at 10:01 AM  |  zacks.comhttps://www.zacks.com/stock/news/2986234/investors-heavily-search-vertex-pharmaceuticals-incorporated-vrtx-here-is-what-you-need-to-know?cid=cs-stocknewsapi-ft-fundamental_analysis|most_searched_stocks_v1-2986234
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Sold Rep. David Taylor
September 8 at 2:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/congress-vertex-pharmaceuticals-nasdaq-vrtx-stock-sold-rep-david-taylor-2026-09-08/
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
September 7 at 2:30 PM  |  247wallst.comhttps://247wallst.com/investing/etf/2026/09/07/ibb-just-beat-the-sp-500-by-22-points-in-three-months-are-you-late-to-the-party/
Rep. David Taylor discloses 6 new Congressional stock trades
September 7 at 2:10 PM  |  finbold.comF
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 94,060 Vertex Pharmaceuticals Incorporated $VRTX
September 7 at 6:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-virginia-retirement-systems-et-al-buys-shares-of-94060-vertex-pharmaceuticals-incorporated-vrtx-2026-09-07/
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Hsbc Holdings PLC
September 7 at 4:48 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-acquired-by-hsbc-holdings-plc-2026-09-07/
2,409 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Formuepleje A S
September 7 at 4:24 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-2409-shares-in-vertex-pharmaceuticals-incorporated-vrtx-purchased-by-formuepleje-a-s-2026-09-07/
California State Teachers Retirement System Buys 190,118,003 Shares of Vertex Pharmaceuticals Incorporated $VRTX
September 7 at 4:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-buys-190118003-shares-of-vertex-pharmaceuticals-incorporated-vrtx-2026-09-07/
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Amundi
September 7 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-purchased-by-amundi-2026-09-07/
Saudi Central Bank Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-saudi-central-bank-raises-stock-holdings-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-06/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amgen stock logo

Amgen NASDAQ:AMGN

$384.43 -6.84 (-1.75%)
As of 10:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

CSL stock logo

CSL OTCMKTS:CSLLY

$30.25 -0.75 (-2.42%)
As of 10:25 AM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$143.86 -1.79 (-1.23%)
As of 10:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$518.12 -3.00 (-0.57%)
As of 10:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas